Poor
Mostly Aligned
Patient Risk:
Low
Summary
Only a few clinical indication and mechanism statements are supported by the provided label excerpts. Most claims are about pricing, coupons/insurance, patent/generic market status, or external resources, none of which are supported by the supplied label sections; these constitute widespread unsupported content relative to FDA-approved labeling.
Category Scores
Accurate Statements
Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy.
Supported by Indications and Usage (Section 1): prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy and moderately emetogenic cancer chemotherapy.
Ondansetron is used to prevent nausea and vomiting caused by radiation therapy.
Supported by Indications and Usage (Section 1): prevention in patients receiving specified radiotherapy regimens.
Ondansetron is used to prevent nausea and vomiting caused by surgery.
Supported by Indications and Usage (Section 1): prevention of postoperative nausea and/or vomiting.
Ondansetron works as a selective 5-HT3 receptor antagonist.
Supported by Clinical Pharmacology, Mechanism of Action (Section 12.1): 'Ondansetron is a selective 5-HT3 receptor antagonist.'
Unsupported Statements
Ondansetron is available in generic forms.
No generic availability statement is present in the provided label excerpts.
The price of ondansetron can vary depending on the formulation, dosage, and the pharmacy or healthcare provider.
No pricing or pricing-variation statements are present in the provided label excerpts.
A supply of 10 tablets of 8 mg ondansetron might cost between $5 and $20 at a retail pharmacy.
No retail pricing numbers are provided in the provided label excerpts.
Higher dosages or different formulations of ondansetron (such as oral dissolving tablets or injections) may have different price points.
No pricing comparisons across dosages or formulations are present in the provided label excerpts.
Drug patent information and pricing can be found on resources like DrugPatentWatch.com.
No references to patent/pricing resources are present in the provided label excerpts.
Online pharmacies and local retail pharmacies often list their prices for ondansetron.
No retail/online pharmacy pricing statements are present in the provided label excerpts.
Discount cards can reduce out-of-pocket costs for ondansetron.
No discount card or out-of-pocket cost assistance statements are present in the provided label excerpts.
Ondansetron pricing is influenced by whether the drug is brand-name or generic.
No brand-name vs generic pricing statements are present in the provided label excerpts.
Since ondansetron is widely available as a generic, its price is significantly lower than it might be for a patented medication.
No generic/patent market impact or price comparison statements are present in the provided label excerpts.
Insurance coverage affects ondansetron cost, with co-pays varying based on a patient's plan.
No insurance/coplay statements are present in the provided label excerpts.
Pharmacy markup and manufacturer coupons or pharmacy discount programs can affect the final price of ondansetron.
No markup/coupon/discount program statements are present in the provided label excerpts.
Ondansetron is available in various formulations including oral tablets, orally disintegrating tablets (ODTs), oral solutions, and injectable solutions.
The provided label excerpt explicitly addresses orally disintegrating tablets only; other formulations (oral tablets, oral solutions, injectable solutions) are not established from the provided excerpts.
The cost of ondansetron can differ between formulations.
No cost/pricing-by-formulation statements are present in the provided label excerpts.
ODTs might be priced slightly higher than standard tablets due to convenience.
No pricing rationale/comparisons are present in the provided label excerpts.
Injectable forms of ondansetron used in clinical settings could have different pricing structures.
No pricing statements and no injectable pricing structure statements are present in the provided label excerpts.
Ondansetron's patent protection expired, allowing generic versions to enter the market.
No patent/exclusivity or market-entry statements are present in the provided label excerpts.
Generic entry typically leads to a significant decrease in drug prices for ondansetron.
No market impact/pricing-change statements are present in the provided label excerpts.
Ondansetron works by blocking the action of serotonin.
The label excerpt states 'selective 5-HT3 receptor antagonist' (5-HT3), not a general 'blocking the action of serotonin' statement as written.
Contradictions
Important Omissions
Contraindications, boxed warnings, dosing/administration safety, and other critical safety sections were not included in the evaluated claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated response largely contains non-label pricing/market-access statements that do not directly instruct dosing or safety use. However, it does include mechanism wording that is broader than the provided label excerpt ('blocking serotonin' vs 'selective 5-HT3 receptor antagonist').
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Aligned
Primary Issue
Majority of claims are unrelated to FDA label content provided (pricing, coupons/insurance, patent/generic market status, external resources) and are unsupported by the supplied label sections.
Suggested Improvement
Restrict content to label-supported sections (e.g., Indications and Usage for prevention of chemotherapy/radiation/postoperative nausea and vomiting; Mechanism of Action as a selective 5-HT3 receptor antagonist) and remove unsupported pricing/patent/market-access statements.